Twin Capital Management Inc. reduced its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,350 shares of the medical research company’s stock after selling 140 shares during the period. Twin Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $4,772,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,114,297 shares of the medical research company’s stock worth $194,411,000 after purchasing an additional 5,725 shares during the last quarter. First Houston Capital Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth about $689,000. Federated Investors Inc. PA boosted its stake in shares of Thermo Fisher Scientific by 531.7% during the 2nd quarter. Federated Investors Inc. PA now owns 51,088 shares of the medical research company’s stock worth $8,913,000 after purchasing an additional 43,000 shares during the last quarter. Graybill Bartz & Assoc Ltd. boosted its stake in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. Graybill Bartz & Assoc Ltd. now owns 20,295 shares of the medical research company’s stock worth $3,541,000 after purchasing an additional 175 shares during the last quarter. Finally, Peddock Capital Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 16.1% during the 2nd quarter. Peddock Capital Advisors LLC now owns 8,836 shares of the medical research company’s stock worth $1,542,000 after purchasing an additional 1,227 shares during the last quarter. 83.36% of the stock is currently owned by institutional investors.

WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/10/01/twin-capital-management-inc-has-4-77-million-holdings-in-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Inc (TMO) opened at 189.20 on Friday. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $194.30. The firm has a market capitalization of $73.81 billion, a PE ratio of 32.96 and a beta of 1.05. The firm’s 50-day moving average is $181.07 and its 200-day moving average is $171.15.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.03 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc will post $9.34 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is 10.45%.

Several research firms have issued reports on TMO. Jefferies Group LLC reaffirmed a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 target price on the stock. Barclays PLC reissued an “overweight” rating and issued a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price on the stock in a research report on Thursday, September 21st. Finally, Cowen and Company reissued an “outperform” rating and issued a $220.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $202.21.

In related news, Director Jim P. Manzi sold 11,318 shares of the business’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $172.94, for a total value of $1,957,334.92. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at approximately $6,702,635.58. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director C Martin Harris sold 360 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the sale, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last three months, insiders sold 52,738 shares of company stock valued at $9,302,112. 0.49% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.